Results 41 to 50 of about 44,864 (262)

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Nature Communications, 2021
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I ...
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno   +18 more
doaj   +1 more source

Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]

Acta Haematologica, 2003
Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to separate the graft-versus-leukemia (GVL) effect from graft-versus-host disease (GVHD).
Kolb, Hans-Jochem, Schmid, Christoph, Chen, Xiao, Woiciechowski, Anja, Roskrow, Marie, Weber, Martin, Guenther, Wolfgang, Ledderose, Georg, Schleuning, Michael   +8 more
openaire   +4 more sources

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

Bioactive Materials
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against ...
Yun Chang, Mingyang Chang, Xiaoping Bao, Cheng Dong   +3 more
doaj   +1 more source

Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system

Cancer Cell International, 2022
Immunotherapy has changed the treatment landscape for multiple cancer types. In the recent decade, great progress has been made in immunotherapy, including immune checkpoint inhibitors, adoptive T-cell therapy, and cancer vaccines. ICIs work by reversing
Yan Jin, Zhifeng Deng, Ting Zhu
doaj   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

Journal of Translational Medicine, 2005
Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine ...
Yee Cassian
doaj   +1 more source

Adoptive immunotherapy for myeloid malignancies [PDF]

Leukemia Supplements, 2014
In allogeneic stem cell transplantation (allo-SCT), much of the anti-tumor effect is derived from a graft versus tumor (GVT) response that is dependent on donor cell engraftment. In order to attain engraftment large doses of chemotherapy are administered to suppress the host's immune system.
openaire   +2 more sources

Adoptive T-Cell Immunotherapy [PDF]

, 2015
Epstein-Barr virus (EBV) is associated with a range of malignancies involving B cells, T cells, natural killer (NK) cells, epithelial cells, and smooth muscle. All of these are associated with the latent life cycles of EBV, but the pattern of latency-associated viral antigens expressed in tumor cells depends on the type of tumor.
Stephen, Gottschalk, Cliona M, Rooney
openaire   +2 more sources